Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure

J Invest Dermatol. 2021 Dec;141(12):2975-2979. doi: 10.1016/j.jid.2021.04.026. Epub 2021 Jun 5.

Authors

Maria Del Mar Melendez-Gonzalez¹, Judy Hamad², Christopher Sayed³

Affiliations

¹ Universidad Central del Caribe, Bayamón, Puerto Rico, USA.
² UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
³ Department of Dermatology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Electronic address: christopher_sayed@email.unc.edu.

PMID: 34097922
DOI: 10.1016/j.jid.2021.04.026

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Adalimumab / therapeutic use
Adult
Antibodies, Monoclonal / administration & dosage*
Female
Hidradenitis Suppurativa / drug therapy*
Hidradenitis Suppurativa / immunology*
Humans
Inflammation
Male
Middle Aged
Retrospective Studies
Treatment Failure
Treatment Outcome
Tumor Necrosis Factor Inhibitors / pharmacology*
Tumor Necrosis Factor-alpha / therapeutic use*

Substances

Antibodies, Monoclonal
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha
golimumab
Adalimumab

Grants and funding

R21 AR075996/AR/NIAMS NIH HHS/United States